Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Supernus Pharmaceuticals
ISIN US8684591089
|WKN A1JX3U
Market cap (in EUR)
2,513 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Overview
Description
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 2,513 m |
| EPS, EUR | -0.31 |
| P/B ratio | 2.8 |
| P/E ratio | 48.7 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 612 m |
| Net income, EUR | 68 m |
| Profit margin | 11.16% |
What ETF is Supernus Pharmaceuticals in?
There are 31 ETFs which contain Supernus Pharmaceuticals. All of these ETFs are listed in the table below. The ETF with the largest weighting of Supernus Pharmaceuticals is the iShares Healthcare Innovation UCITS ETF.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.